Robustness Assessment of Oncology Dose-Finding Trials Using the Modified Fragility Index
The mFI can be a useful metric assessing the fragility of phase I trials and facilitating robust identification of MTD.
Authors
- Haitao Chu (ORCID: https://orcid.org/0000-0003-0932-598X)
- Lifeng Lin (ORCID: https://orcid.org/0000-0002-3562-9816)
- Heng Zhou (ORCID: https://orcid.org/0000-0003-3611-028X)
- Li Hongjian
- Lei Nie (ORCID: https://orcid.org/0000-0002-7791-9395)
- Amy X. Shi
Institutions
- University of Minnesota (US)
- United States Food and Drug Administration (US)
- University of Arizona (US)
- Pfizer (United States) (US)
- Decision Sciences (United States) (US)
- AstraZeneca (United States) (US)
- Statistical Research (United States) (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-17
- DOI
- https://doi.org/10.3390/cancers16203504
- Citations
- 1
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.71